ReviewInternational journal of chronic obstructive pulmonary disease2014
Bacterial microbiome of lungs in COPD.
Review in International journal of chronic obstructive pulmonary disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04070248 (Investigating the Association Between Altered Lung MicroBiome and HIV-associated Chronic Obstructive Pulmonary Disease in a Ugandan Cohort), which is not on this map. Cited by 74 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Investigating the Association Between Altered Lung MicroBiome and HIV-associated Chronic Obstructive Pulmonary Disease in a Ugandan Cohort
Who cites it
74 citing papers in PubMed, 2 syntheses or guidelines pooled it, 118 citations in OpenAlex.
- Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta-analysis.The Cochrane database of systematic reviews · 2021Pooled it
- Excess costs of comorbidities in chronic obstructive pulmonary disease: a systematic review.PloS one · 2015Pooled it
- Characterisation of microbiota in saliva, bronchoalveolar lavage fluid, non-malignant, peritumoural and tumour tissue in non-small cell lung cancer patients: a cross-sectional clinical trial.Respiratory research · 2020Trial
- Multi-site microbiomes' response to chronic obstructive pulmonary disease.Microbiology spectrum · 2026Article
- Pulmonary infection byFrontiers in cellular and infection microbiology · 2026Article
- Hyperconcentrated mucus in small airways: a mechanistic model for the pathogenesis of paediatric bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Investigation of the Number of Oral Bacteria in Patients with Chronic Obstructive Pulmonary Disease, Asthma, and Asthma and Chronic Obstructive Pulmonary Disease Overlap.Internal medicine (Tokyo, Japan) · 2025Article
- Natural killer cells in the lung: novel insight and future challenge in the airway diseases.ERJ open research · 2025Review
- Omega-3 Fatty Acids and Chronic Lung Diseases: A Narrative Review of Impacts from Womb to Tomb.The Journal of nutrition · 2025Review
- Integrative network pharmacology, transcriptomics, and microbiomics elucidate the therapeutic mechanism ofFrontiers in microbiology · 2025Article
- The Lung Microbiome in COPD and Lung Cancer: Exploring the Potential of Metal-Based Drugs.International journal of molecular sciences · 2023Review
- Chronic Obstructive Pulmonary Disease and the Airway Microbiome: What Respirologists Need to Know.Tuberculosis and respiratory diseases · 2023Article
- Understanding the Relationship of the Human Bacteriome with COVID-19 Severity and Recovery.Cells · 2023Review
- Gut microbiota and COVID-19: A systematic review.Health science reports · 2023Article
- Article
- The microbiome and the gut-lung axis in tuberculosis: interplay in the course of disease and treatment.Frontiers in microbiology · 2023Review
- Gut-Lung Microbiota Interaction in COPD Patients: A Literature Review.Medicina (Kaunas, Lithuania) · 2022Review
- Article
- Machine-learning algorithms for asthma, COPD, and lung cancer risk assessment using circulating microbial extracellular vesicle data and their application to assess dietary effects.Experimental & molecular medicine · 2022Article
- Effect of invasive mechanical ventilation on the diversity of the pulmonary microbiota.Critical care (London, England) · 2022Review
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic obstructive pulmonary disease (COPD) is currently the third leading cause of death in the world. Although smoking is the main risk factor for this disease, only a minority of smokers develop COPD. Why this happens is largely unknown. Recent discoveries by the human microbiome project have shed new light on the importance and richness of the bacterial microbiota at different body sites in human beings. The microbiota plays a particularly important role in the development and functional integrity of the immune system. Shifts or perturbations in the microbiota can lead to disease. COPD is in part mediated by dysregulated immune responses to cigarette smoke and other environmental insults. Although traditionally the lung has been viewed as a sterile organ, by using highly sensitive genomic techniques, recent reports have identified diverse bacterial communities in the human lung that may change in COPD. This review summarizes the current knowledge concerning the lung microbiota in COPD and its potential implications for pathogenesis of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.